rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ICU Medical, Inc.

ICUI · Nasdaq

Health CareMedical DevicesLeading

ICUI stood above a rising 150-day average in 31 of the last 52 weekly readings, including each of the last 17 weeks. It is 8.9% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
17 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$15.8M
Officials’ trades on record
22
Institutions holding
266 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$9.0M$0$2.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

22 disclosed lines: House 21, Senate 1, executive 0; 5 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k6 May 2025filed 6 Jun 2025
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k31 Oct 2024filed 6 Nov 2024
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k14 Feb 2022filed 18 Mar 2022
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39sold$1k–$15k23 Dec 2020filed 11 Jan 2021
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k21 Dec 2020filed 7 Jan 2021
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k25 Sep 2020filed 14 Oct 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$15k–$50k24 Sep 2020filed 14 Oct 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k23 Sep 2020filed 14 Oct 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k31 Mar 2020filed 16 Apr 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39sold$1k–$15k15 Aug 2019filed 11 Sep 2019
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39sold$1k–$15k30 Jul 2019filed 19 Aug 2019
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k26 Jul 2019filed 16 Sep 2019

Insiders

Buy orders, 12 months0
Sale orders, 12 months13
Buyers · sellers0 · 7
WhoDidSharesTraded
Virginia Ruth SanzoneVP, General Counselsold2,202at $167.673 Sep 2026filed 3 Sep 2026
Virginia Ruth SanzoneVP, General Counselsold1,238at $168.443 Sep 2026filed 3 Sep 2026
Virginia Ruth SanzoneVP, General Counselsold724at $169.533 Sep 2026filed 3 Sep 2026
Virginia Ruth SanzoneVP, General Counselsold692at $171.523 Sep 2026filed 3 Sep 2026
Brian Michael BonnellChief Financial Officersold6,381at $175.001 Sep 2026filed 1 Sep 2026
Brian Michael BonnellChief Financial Officersold1,712at $171.0531 Aug 2026filed 31 Aug 2026
Brian Michael BonnellChief Financial Officersold1,914at $172.1231 Aug 2026filed 31 Aug 2026
Brian Michael BonnellChief Financial Officersold4,568at $173.4431 Aug 2026filed 31 Aug 2026
Brian Michael BonnellChief Financial Officersold1,113at $173.9131 Aug 2026filed 31 Aug 2026
Daniel WoolsonVP, GM-Infusion Capitalsold5,417at $181.3313 Aug 2026filed 13 Aug 2026
Ben SousaChief Information Officersold2,250at $178.3212 Aug 2026filed 12 Aug 2026
Elisha W. FinneyDirectorsold378at $182.4811 Aug 2026filed 11 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders266+8 on the quarter
New · exited43 · 35
Reported value$3.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20263,753,409$550.2M+145,087+4.0%
Jupiter Topco LLCnew · filed 14 Aug 20262,781,620$407.8M+2,781,620
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,470,583$215.6M+32,907+2.3%
FULLER & THALER ASSET MANAGEMENT, INC.added · filed 12 Aug 20261,298,127$190.3M+77,588+6.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,123,237$164.7M+11,362+1.0%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20261,053,476$154.4M+69,674+7.1%
STATE STREET CORPadded · filed 7 Aug 20261,024,369$150.2M+56,316+5.8%
SCHRODER INVESTMENT MANAGEMENT GROUPadded · filed 13 Aug 2026739,138$109.3M+37,858+5.4%
AMERIPRISE FINANCIAL INCadded · filed 14 Aug 2026689,573$101.1M+83,845+13.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026660,423$96.8M+49,204+8.1%
31 Mar 2023 – 30 Jun 2026
188227266Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Virginia Ruth Sanzone Company insiderVP, General Counsel · last 3 Sep 20260 · 20
Brian Michael Bonnell Company insiderChief Financial Officer · last 1 Sep 20260 · 2
Daniel Woolson Company insiderVP, GM-Infusion Capital · last 13 Aug 20260 · 9
Ben Sousa Company insiderChief Information Officer · last 12 Aug 20260 · 3
Christian B. Voigtlander Company insiderChief Operating Officer · last 11 Aug 20260 · 18
Elisha W. Finney Company insiderDirector · last 11 Aug 20260 · 8
David C. Greenberg Company insiderDirector · last 13 May 20261 · 3
David F. Hoffmeister Company insiderDirector · last 13 May 20260 · 0
Donald Abbey Company insiderDirector · last 13 May 20260 · 0
Kolleen T. Kennedy Company insiderDirector · last 13 May 20260 · 0
Laurie Hernandez Company insiderDirector · last 13 May 20260 · 0
Vivek Jain Company insiderChairman and CEO · last 15 Mar 20262 · 35

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202536.8%
Operating profit marginFY 2025 · to 31 Dec 20251.9%
Free cash flow marginFY 2025 · to 31 Dec 20254.1%
Return on capital employedFY 2025 · to 31 Dec 20251.2%
Debt to equityFY 2025 · to 31 Dec 20250.60×
Interest coverFY 2025 · to 31 Dec 20250.46×
Research spendFY 2025 · to 31 Dec 20253.9%
Share count trendFY 2025 · to 31 Jan 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$308.0M
Free cash flowFY 2025 · to 31 Dec 2025$91.8M

Analyst forecasts

No analyst forecasts yet.